Search filters

Filters

Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 152
  • 17
  • 402
  • 1246
  • 593
  • 29
  • 49
  • 3
  • 1172
  • 1247
  • 6
  • 4
  • 1249

Found 1253 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).

All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Learn More

TrialX API NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).

All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Learn More
Online study

Test 20260401

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Learn More

Test 20260407

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Learn More

NRG-GI007 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).

All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Learn More

NRG-GI007 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (Circulate-North America).

All genders
Phase II and III: To compare time to DFS event (recurrence, second primary colorectal can cer or death) in ctDNA (+ve) cohort following resection of colon cancer treated with 5-FU (orcapecitabine) and oxaliplatin x 6 months or 5-FU, oxaliplatin and irinotecan x 6 months.
Learn More

API Push Trial without Cancer attribute

All genders
To evaluate the efficacy of ONC201 administered following radiotherapy in participants with H3 K27Mmutant diffuse glioma. To assess plasma concentrations and estimate PK parameters for ONC201. To evaluate the efficacy of ONC201 using RANO-LGG criteria. To evaluate the impact of ONC201 treatment on health care resource utilization.
Learn More

CART-38 in Adult AML and MM Patients - 1 (ALLOHA)

All genders
Phase 1
Interventional
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating dose regimen of up to 2 doses of TSC-100 and TSC-101 in patients with AML, MDS, or ALL following HCT from a haploidentical donor, …
Learn More

EC17 for Intraoperative Imaging in Occult Ovarian Cancer

All genders
Phase 1
Interventional
The overall prevalence of Ovarian Cancer in the United States according to the US SEER Registry is 182,710 women. Ovarian cancer also has the highest mortality rate of the gynecological cancers. The overall five-year survival rate is 45% and for Stages III and IV it is only 20-25%. The majority …
Learn More

CART-38 in Adult AML and MM Patients - 1

All genders
Phase 1
Interventional
Primary hyperparathyroidism is a significant medical and public health problem in the world and affects approximately 100,000 new patients in the United States alone. If left untreated this can lead to renal stones, osteoporosis, fatigue, and depression. The best treatment for primary hyperparathyroidism is surgical parathyroidectomy. However surgical parathyroidectomy can …
Learn More
1241 - 1250 of 1253